BR112022006643A2 - Formulações de liberação controlada de substâncias fisiologicamente ativas altamente lipofílicas - Google Patents

Formulações de liberação controlada de substâncias fisiologicamente ativas altamente lipofílicas

Info

Publication number
BR112022006643A2
BR112022006643A2 BR112022006643A BR112022006643A BR112022006643A2 BR 112022006643 A2 BR112022006643 A2 BR 112022006643A2 BR 112022006643 A BR112022006643 A BR 112022006643A BR 112022006643 A BR112022006643 A BR 112022006643A BR 112022006643 A2 BR112022006643 A2 BR 112022006643A2
Authority
BR
Brazil
Prior art keywords
active substances
physiologically active
controlled release
release formulations
highly lipophilic
Prior art date
Application number
BR112022006643A
Other languages
English (en)
Portuguese (pt)
Inventor
Nowak Mirko
Jesko Nowak Jay
Grave Annette
Wentzlaff Monika
Barthold Sarah
Geugelin Christian
Original Assignee
Add Advanced Drug Delivery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Add Advanced Drug Delivery Tech Ltd filed Critical Add Advanced Drug Delivery Tech Ltd
Publication of BR112022006643A2 publication Critical patent/BR112022006643A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112022006643A 2019-10-16 2020-10-16 Formulações de liberação controlada de substâncias fisiologicamente ativas altamente lipofílicas BR112022006643A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19203580.6A EP3808341A1 (de) 2019-10-16 2019-10-16 Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen
PCT/EP2020/079248 WO2021074403A1 (de) 2019-10-16 2020-10-16 Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen

Publications (1)

Publication Number Publication Date
BR112022006643A2 true BR112022006643A2 (pt) 2022-07-12

Family

ID=68281185

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022006643A BR112022006643A2 (pt) 2019-10-16 2020-10-16 Formulações de liberação controlada de substâncias fisiologicamente ativas altamente lipofílicas

Country Status (10)

Country Link
US (1) US20240139215A1 (enExample)
EP (2) EP3808341A1 (enExample)
JP (2) JP7778069B2 (enExample)
CN (1) CN114945353A (enExample)
AU (1) AU2020365443B2 (enExample)
BR (1) BR112022006643A2 (enExample)
CA (1) CA3157654A1 (enExample)
IL (1) IL292018A (enExample)
MX (1) MX2022004523A (enExample)
WO (1) WO2021074403A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3808336A1 (de) * 2019-10-16 2021-04-21 ADD Advanced Drug Delivery Technologies, Ltd. Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen
AU2021400338A1 (en) 2020-12-17 2023-07-13 Nalu Bio, Inc. Synthesis of cannabidiol and analogs thereof, and related compounds, formulations, and methods of use
GB2618322A (en) * 2022-04-29 2023-11-08 113 Botanicals Ltd Compositions and methods
US12636296B1 (en) 2025-07-17 2026-05-26 Nalu Bio, Inc. Cannabinol analogs and their use as pharmacologically active agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1361864T3 (en) * 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
JPWO2002069957A1 (ja) * 2001-03-01 2004-07-02 グレラン製薬株式会社 フェノフィブラート含有組成物
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
US9943491B2 (en) 2013-10-29 2018-04-17 Echo Pharmaceuticals B.V. Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
WO2015065547A1 (en) * 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
DE102014213548A1 (de) * 2014-07-11 2016-01-14 Hans Brammer Cannabispräparat
JP6581649B2 (ja) * 2014-08-11 2019-09-25 ペロラ ゲーエムベーハーＰｅｒｏｒａ Ｇｍｂｈ 粒子を含む製剤
IL246790A0 (en) * 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
US20190201350A1 (en) 2016-08-15 2019-07-04 Corr-Jensen Inc. Time release of fat-soluble actives
JP2019137614A (ja) * 2018-02-06 2019-08-22 富士フイルム株式会社 経口用医薬組成物及びその製造方法
DE102019100483A1 (de) * 2019-01-10 2020-07-16 Lts Lohmann Therapie-Systeme Ag Oraler Dünnfilm

Also Published As

Publication number Publication date
IL292018A (en) 2022-06-01
JP7778069B2 (ja) 2025-12-01
WO2021074403A1 (de) 2021-04-22
CA3157654A1 (en) 2021-04-22
CN114945353A (zh) 2022-08-26
AU2020365443A1 (en) 2022-06-02
EP3808341A1 (de) 2021-04-21
EP4045014A1 (de) 2022-08-24
US20240139215A1 (en) 2024-05-02
AU2020365443B2 (en) 2026-06-04
JP2022553653A (ja) 2022-12-26
JP2025182116A (ja) 2025-12-11
MX2022004523A (es) 2022-09-19

Similar Documents

Publication Publication Date Title
BR112022024943A2 (pt) Composição oral efervescente compreendendo um ingrediente ativo
CL2019002671A1 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1.
CY1126152T1 (el) Ενωσεις-αναστολεις της rip1 και μεθοδοι παρασκευης και χρησης αυτων
BR112018006259A2 (pt) "adjunto compressível com estruturas de suporte intermediárias"
BR112015026549A2 (pt) forma de dosagem à prova de violação contendo uma ou mais partículas
MX2022005509A (es) Compuestos inhibidores de rip1 heterociclicos.
BR112019007798A2 (pt) veículo de liberação oral
BR112017024517A2 (pt) compostos de tetraidroquinolinona como moduladores ror gama
BR112015029616A2 (pt) forma de dosagem resistente à adulteração com perfil de liberação bimodal
AR054581A1 (es) Composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion
BR112019001923A2 (pt) moduladores de nmda de espiro-lactama e métodos de sua utilização
BR112018006368A2 (pt) composição para desempenho melhorado
MX2022004523A (es) Formulaciones de liberacion controlada para sustancias fisiologicamente activas altamente lipofilicas.
BR112015011430A2 (pt) composição para liberação imediata e prolongada
BR112017024783A2 (pt) composições contraceptivas e métodos para eficácia melhorada e modulação dos efeitos colaterais
CR20230259A (es) Anticuerpos de cadena pesada que se unen al receptor de folato alfa
BR112022010872A2 (pt) Produtos orais
PA8659101A1 (es) Uso de colorantes de cianina para el diagnostco de enfermedades proliferativas
BR112015024271A2 (pt) sistema de fornecimento transdérmico
CL2020002101A1 (es) Formulaciones de liberación sostenida de ácido bempedoico.
BR112017006180A2 (pt) composições de redução de mau odor
FR3058059B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
MX2022004882A (es) Composicion farmaceutica que comprende selexipag.
SA520420261B1 (ar) تركيبات إرنوماب واستخداماتها
BR112019001207A2 (pt) composição vaginal compreendendo uma combinação de estrogênio e vitamina d

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]